Published in Health Business Week, February 16th, 2007
DelSite, a wholly-owned subsidiary of Carrington, has been developing a platform for the development of a vaccine for an H5N1 flu pandemic with funding from the National Institute of Allergy and Infectious Disease, Department of Human Health Services (NIAID, DHHS). GelVac is the platform for nasal powder delivery of preservative-free...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week